{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2018"],"condition":["Colon Neoplasms","Colon Cancer","Colonic Cancer","Cancer of the Colon","Neoplasms, Colonic","Neoplasms","Colonic Neoplasms"],"disease":["Colon Neoplasms","Colonic Cancer","Colon Cancer","Neoplasms, Colonic","Cancer Of The Colon","Neoplasms","Colonic Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2266868"],"location":["United States"],"study_start_month":["3"],"keyword":["Palbociclib","Metastatic colon cancer","Cetuximab"],"repository":["ECRIN MDR"],"study_status":["Active, not recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Palbociclib and Cetuximab in Metastatic Colorectal Cancer","description":"This research study is designed to provide a better understanding of study drugs cetuximab (Erbitux) and palbociclib when used in combination to treat patients with metastatic colon cancer.","dates":{"creation":"2018-03-15"},"accession":"2266868","cross_references":{"ClinicalTrials___gov":["NCT03446157"]}}